174 related articles for article (PubMed ID: 25127130)
1. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
[TBL] [Abstract][Full Text] [Related]
2. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
[TBL] [Abstract][Full Text] [Related]
3. An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.
Joseph BC; Miyazawa BY; Esmon CT; Cohen MJ; von Drygalski A; Mosnier LO
Blood Adv; 2022 Feb; 6(3):959-969. PubMed ID: 34861695
[TBL] [Abstract][Full Text] [Related]
4. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
[TBL] [Abstract][Full Text] [Related]
5. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.
von Drygalski A; Bhat V; Gale AJ; Averell PM; Cramer TJ; Elias DJ; Griffin JH; Mosnier LO
Blood Adv; 2020 Aug; 4(15):3716-3727. PubMed ID: 32777068
[TBL] [Abstract][Full Text] [Related]
6. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C.
Gale AJ; Xu X; Pellequer JL; Getzoff ED; Griffin JH
Protein Sci; 2002 Sep; 11(9):2091-101. PubMed ID: 12192065
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
Mosnier LO; Yang XV; Griffin JH
J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949
[TBL] [Abstract][Full Text] [Related]
8. C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities.
Yamashita A; Zhang Y; Sanner MF; Griffin JH; Mosnier LO
J Thromb Haemost; 2020 May; 18(5):1027-1038. PubMed ID: 32017367
[TBL] [Abstract][Full Text] [Related]
9. Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.
Gale AJ; Bhat V; Pellequer JL; Griffin JH; Mosnier LO; Von Drygalski A
Pharm Res; 2016 Jun; 33(6):1517-26. PubMed ID: 26960296
[TBL] [Abstract][Full Text] [Related]
10. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.
Mosnier LO; Gale AJ; Yegneswaran S; Griffin JH
Blood; 2004 Sep; 104(6):1740-4. PubMed ID: 15178575
[TBL] [Abstract][Full Text] [Related]
12. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.
Griffin JH; Mosnier LO; Fernández JA; Zlokovic BV
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2143-2151. PubMed ID: 27758767
[TBL] [Abstract][Full Text] [Related]
13. Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin.
Segers K; Dahlbäck B; Rosing J; Nicolaes GA
J Biol Chem; 2008 Aug; 283(33):22573-81. PubMed ID: 18519572
[TBL] [Abstract][Full Text] [Related]
14. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites.
Gale AJ; Heeb MJ; Griffin JH
Blood; 2000 Jul; 96(2):585-93. PubMed ID: 10887122
[TBL] [Abstract][Full Text] [Related]
15. Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va.
Tran S; Norstrøm E; Dahlbäck B
J Biol Chem; 2008 Mar; 283(11):6648-55. PubMed ID: 18198180
[TBL] [Abstract][Full Text] [Related]
16. Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy.
Campbell JE; Meledeo MA; Cap AP
PLoS One; 2014; 9(6):e99181. PubMed ID: 24921658
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C.
Griffin JH; Fernández JA; Gale AJ; Mosnier LO
J Thromb Haemost; 2007 Jul; 5 Suppl 1():73-80. PubMed ID: 17635713
[TBL] [Abstract][Full Text] [Related]
18. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.
Wang Y; Thiyagarajan M; Chow N; Singh I; Guo H; Davis TP; Zlokovic BV
Stroke; 2009 May; 40(5):1864-9. PubMed ID: 19057019
[TBL] [Abstract][Full Text] [Related]
19. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zhang G; Ma Z; Cao L; Zuo B; Zhou L; Huang L; Niu S; Xia Z; Zhou X; Bai X; Esmon NL; Ruan C; Xia L; Han Y; Esmon CT; Wu D; Xu J
Blood Adv; 2022 Jun; 6(11):3304-3314. PubMed ID: 35390147
[TBL] [Abstract][Full Text] [Related]
20. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
